River Street Advisors LLC Purchases Shares of 5,240 Edwards Lifesciences Corporation $EW

River Street Advisors LLC purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, HoldingsChannel.com reports. The firm purchased 5,240 shares of the medical research company’s stock, valued at approximately $410,000.

A number of other hedge funds also recently made changes to their positions in EW. Jennison Associates LLC lifted its holdings in shares of Edwards Lifesciences by 34.3% during the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after acquiring an additional 2,576,383 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Edwards Lifesciences by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock valued at $491,673,000 after acquiring an additional 264,311 shares in the last quarter. Nuveen LLC acquired a new position in shares of Edwards Lifesciences during the 1st quarter valued at $330,881,000. Invesco Ltd. lifted its holdings in shares of Edwards Lifesciences by 2.6% during the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after acquiring an additional 107,241 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Edwards Lifesciences by 5.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock valued at $287,140,000 after acquiring an additional 198,882 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Ratings Changes

Several research firms recently weighed in on EW. Wall Street Zen lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a report on Monday. Piper Sandler lifted their target price on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, July 25th. Robert W. Baird lifted their target price on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, July 25th. Mizuho lifted their price target on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Finally, Canaccord Genuity Group lifted their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $86.61.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $76.66 on Friday. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00. The company has a market capitalization of $45.01 billion, a price-to-earnings ratio of 11.03, a price-to-earnings-growth ratio of 3.67 and a beta of 1.05. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm’s fifty day moving average price is $78.55 and its 200 day moving average price is $75.89.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.